Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension.

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Resistant hypertension (RH) presents significant challenges in cardiovascular disease management.
• Aldosterone synthase inhibitors (ASIs) offer a novel therapeutic approach by targeting aldosterone synthesis.
• Baxdrostat is a selective ASI targeting CYP11B2, minimizing off-target hormonal effects.

Purpose of the Study:

• To evaluate the efficacy and safety of baxdrostat in patients with resistant hypertension.
• To assess the dose-dependent effects of baxdrostat on aldosterone and blood pressure.
• To explore the therapeutic potential of baxdrostat in aldosterone-driven hypertension.

Main Methods:

• Phase 2 clinical trials (BrigHTN and HALO) were conducted to assess baxdrostat's effects.
• Patients with resistant hypertension received varying doses of baxdrostat or placebo.
• Plasma aldosterone levels, blood pressure, and safety parameters were monitored.

Main Results:

• Baxdrostat demonstrated a dose-dependent reduction in plasma aldosterone levels while preserving cortisol.
• Significant reductions in systolic and diastolic blood pressure were observed in the BrigHTN trial with the 2 mg dose.
• The HALO trial suggested potential confounding factors like improved adherence affecting results.
• Baxdrostat exhibited a favorable safety profile with mild adverse effects and no significant impact on renal function.

Conclusions:

• Baxdrostat is a promising therapeutic option for aldosterone-driven hypertension, particularly in treatment-resistant cases.
• Its selective inhibition of aldosterone synthesis offers a favorable risk-benefit profile.
• Further research is ongoing to evaluate baxdrostat in chronic kidney disease and primary hyperaldosteronism.